Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1956827 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $124.33Day +4.62%1Y +75.5%Off 52W high −16.5%Vol (1Y) 85.2%
Daily closing price, split-adjusted to the current basis; 2.7y shown of 689 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest5.1% of sh out |
| Days to cover2.4d |
| 13F net flow (QoQ)−6.65% |
| Top-10 13F concentration48.0% |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)€4.6M |
| Earnings (TTM)-€336.1M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (EUR). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−7.8% |
| 1Y+75.5% |
| Since incept. (ann.)+165.1% |
Total return through 2026-07-30 · series begins 2023-10-20. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)85.2% |
| Ann. volatility (3Y)361.0% |
| Sharpe (1Y)1.14 |
| Sharpe (3Y)0.74 |
| Max drawdown (1Y)−50.1% |
| Max drawdown (3Y)−67.5% |
| Beta (3Y vs SPY)1.20 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 6.5M | $722M | — | −8.9% |
| UBS Group AG | 4.5M | $506M | — | +2.8% |
| Darwin Global Management, Ltd. | 3.5M | $352M | — | +9.1% |
| MORGAN STANLEY | 1.7M | $190M | — | −45.9% |
| Vestal Point Capital, LP | 1.5M | $167M | — | −21.1% |
| Caligan Partners LP | 1.5M | $163M | — | +0.7% |
| ADAR1 Capital Management, LLC | 1.4M | $155M | — | +5.8% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.3M | $147M | — | +31.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: this line files 20-F annual reports only — a foreign private issuer whose US listing trades as ADSs (depositary receipts), while its cover-page share count is in ORDINARY shares. The depositary ratio is not in our data. The count we hold for this line is 78,536,412 shares (as of 2025-12-31, source dei). Dividing one by the other is wrong by the whole ratio (a 5:1 ADR reads one fifth of the true percentage), so the percentage is withheld rather than served wrong. Holder share counts are shown as filed.
No reported quarters on file for ABVX.
